Skip to main content

A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multiple Sclerosis Spasticity

Recruiting · Phase 2 · NCT06782490

Conditions: Multiple Sclerosis Spasticity

At a glance

Research payments reported, 2025
$16,072
U.S. investigators named
10
Sites paid
10
Planned or actual enrollment
200

About the trial

Sponsor
Celgene
Tested
BMS-986368 (drug), Placebo (drug)
Dates
Started 2025-06-05; completion 2027-06-09
Results posted
Not yet

The purpose of this study is to evaluate the efficacy, safety, and tolerability of BMS-986368 in participants with Multiple Sclerosis Spasticity

From ClinicalTrials.gov, last updated 2026-10-27. Full record, eligibility and contacts (opens in a new tab)

Industry funding

E.r. Squibb & Sons, L.l.c. reported $16,072 in research payments for this study in 2025 (10 payments).

Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.

U.S. investigators named on this study

Clinicians the company named as principal investigators in its Open Payments reports.

Sites paid to run it

  • Puerto Rico Multiple Sclerosis Center $4,419
  • Neurology Center of New England, PC $2,193
  • Hope Neurology, PLLC $1,653
  • University of Kansas Medical Center $1,310
  • University of Cincinnati $1,227
  • Aqualane Clinical Research $1,107
  • Perseverance Research Center $1,068
  • Evergreenhealth Medical Center $1,047
  • Washington University School of Medicine Cardiovascular Division $1,041
  • Usf $1,006

Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.